The impact of the SGLT2 inhibitor on cardiovascular risk factors in patients with type 2 diabetes, an explanatory randomized trial
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000021669
- Lead Sponsor
- Tokyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Not provided
1. Diagnosed as diabetes within the last 6 months 2. Taking SGLT2 inhibitors 3. Taking diuretics 4. Pituitary dysfunction or adrenal insufficiency 5. Excessive alcohol intake 8. eGFR < 30mL / min / 1.73m2(MDRD) 9. AST >= 165 or ALT >= 210 10. Serum C-peptide < 0.5ng / mL 11. History of severe hypoglycemia within the last 3 months 12. Systolic blood pressure >= 200 mmHg or diastolic blood pressure >=120 mmHg 13. Secondary hypertension 14. Vitreous hemorrhage, unstable proliferative diabetic retinopathy 15. Severe diabetic neuropathy 16. Positive anti-GAD antibody 17. During pregnancy 18. Chronic atrial fibrillation 19. History of pyelonephritis 20. Claustrophobia, pacemaker, the metal in the body, weighing 150 kg or more 21. Unable to hold the breath longer than 20 seconds
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intramyocardial lipid deposition measured by magnetic resonance spectroscopy (MRS): Time Frame of 8 weeks
- Secondary Outcome Measures
Name Time Method